

GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS



HLC174A
October 2015

Usha Nagavarapu
Project Analyst

ISBN: 1-62296-167-6



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE AND FORMAT	2
INTENDED AUDIENCE	3
METHODOLOGY	3
RELATED BCC RESEARCH REPORTS	3
ANALYST'S CREDENTIALS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, THROUGH 2020 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, 2014-2020 (\$ MILLIONS)</i>	7
CHAPTER 3 CANCER	9
WHAT IS CANCER?	9
CAUSES OF CANCER GROWTH	10
CANCER TREATMENT STRATEGIES	11
COMMON TREATMENTS AND PROBLEMS	11
Surgery	11
Chemotherapy	12
Radiation Treatment	12
Hormone Therapy	13
Targeted Therapy	13
GASTRIC CANCER	15
CHAPTER 4 INTRODUCTION TO GASTRIC CANCER	17
<i>TABLE 1 MAIN CATEGORIES OF CANCER</i>	17
DIGESTIVE SYSTEM AND CANCER	18
ESOPHAGEAL CANCER	18
GASTRIC CANCER GLOBAL INCIDENCE	21
SUBTYPES AND CHARACTERISTICS	22
SMALL INTESTINE CANCER	23
STOMACH CANCER/GASTRIC CANCER OVERVIEW	26
<i>TABLE 2 TYPES OF STOMACH CANCER</i>	29
<i>TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER</i>	29
<i>TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER</i>	30
CAUSES	32
<i>TABLE 5 RISK FACTORS</i>	32
<i>TABLE 6 CAUSES OF GASTRIC CANCER</i>	33
SYMPTOMS	33
<i>TABLE 7 SYMPTOMS</i>	33
THERAPEUTIC OPTIONS	34

TOPIC	PAGE NO.
RELATED CANCERS AND OVERVIEW	35
KIDNEY CANCER	35
TARGETED THERAPIES FOR KIDNEY CANCER	39
<i>TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER</i>	40
SORAFENIB (NEXAVAR)	40
SUNITINIB (SUTENT)	40
TEMSIROLIMUS (TORISEL)	41
EVEROLIMUS (AFINITOR)	41
BEVACIZUMAB (AVASTIN)	41
PAZOPANIB (VOTRIENT)	41
AXITINIB (INLYTA)	42
LIVER	42
PANCREATIC CANCER	46
SUMMARY	51
CHAPTER 5 GASTRIC CANCER SCREENING, DIAGNOSIS AND MARKET	53
SCREENING	53
SCREENING METHODS	53
<i>TABLE 9 GASTRIC SCREENING METHODS</i>	54
SCREENING AND BENEFITS	55
SCREENING MODALITIES	55
Barium-Meal Gastric Photofluorography	55
Gastric Endoscopy	56
Serum Pepsinogen	56
GASTRIC SCREENING IN UNITED STATES	57
GASTRIC CANCER SCREENING WORLDWIDE	57
Conclusions	58
CHAPTER 6 GASTRIC SCREENING AND DIAGNOSIS MARKET	60
<i>TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH CANCER WORLDWIDE, 2012 (THOUSANDS)</i>	60
SCREENING	61
<i>TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET, THROUGH 2020 (\$ MILLIONS)</i>	62
DIAGNOSIS AND PROGNOSIS	64
TESTS	64
<i>TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER</i>	64
IMAGING TESTS	65
Upper Gastrointestinal (GI) Series	66
Computed Tomography (CT or CAT) Scan	66
Magnetic Resonance Imaging (MRI) Scan	66
Positron Emission Tomography (PET) Scan	67
Chest X-Ray	67
Laparoscopy	67
Helicobacter Pylori	68
<i>TABLE 13 TESTS USED TO DETECT H. PYLORI</i>	68
Lab Tests	68
Costs	68

TOPIC	PAGE NO.
<i>TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 (MILLIONS)</i>	68
SERUM PEPSINOGEN PREDICTS GASTRIC ADENOCARCINOMA	70
CHAPTER 7 GASTRIC CANCER TREATMENT OPTIONS	72
CURRENT PRACTICES	72
<i>TABLE 15 TYPES OF STANDARD TREATMENT</i>	72
CHEMOPREVENTION	72
ANTIOXIDANTS	72
ANTIBIOTICS	73
Non-Steroidal Anti-Inflammatory Drugs (Including Aspirin)	73
STAGING	73
Sentinel Lymph Node Mapping	73
Surgery	74
Chemotherapy	74
Radiation Therapy	75
Chemoradiation	75
TARGETED THERAPY	75
Drugs Approved for Stomach (Gastric) Cancer	75
<i>TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER</i>	76
PROGNOSIS	76
PREVENTION	76
CHEMOTHERAPY DRUGS AND COMBINATIONS	77
TARGETED THERAPY OVERVIEW	77
Pembrolizumab	78
Ramucirumab	79
Afinitor (Everolimus)	81
Apatinib	85
FAILED DRUGS	86
Cetuximab	86
Tykerb (Lapatinib)	86
Expected Treatment Outcomes	87
GASTROINTESTINAL CANCER: MONOCLONAL ANTIBODIES	87
<i>TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY THERAPEUTICS</i>	88
<i>TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER TREATMENT</i>	88
<i>TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 (\$ MILLIONS)</i>	89
<i>FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 (\$ MILLIONS)</i>	89
<i>TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT</i>	91
AVASTIN (BEVACIZUMAB)	91
HERCEPTIN (TRASTUZUMAB)	92
VECTIBIX (PANITUMUMAB)	94
CHAPTER 8 MARKET DYNAMICS AND OVERVIEW	96
<i>TABLE 21 CANCER KEY FACTS</i>	96

TOPIC	PAGE NO.
STANDARD TREATMENTS	97
GLOBAL CANCER MARKET TRENDS	97
TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLIONS OF PATIENTS)	98
FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLION PATIENTS)	98
TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND 2030 (MILLIONS)	99
FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND 2030 (MILLIONS)	99
TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015	100
GLOBAL ONCOLOGY MARKET	101
TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	102
FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 (\$ MILLIONS)	102
CANCER DRUGS: PAST PERFORMANCE	103
TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013 (\$ MILLIONS/%)	105
EMERGING MARKETS	106
TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 (\$ MILLIONS)	106
FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 (\$ MILLIONS)	106
GASTRIC CANCER TREATMENT COSTS	109
Drugs Approved for Stomach (Gastric) Cancer	110
TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 (\$ MILLIONS)	111
FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 (\$ MILLIONS)	111
TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT	111
TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2020 (\$ MILLIONS)	112
FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2014-2020 (\$ MILLIONS)	112
TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 (\$ MILLIONS)	113
FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 (\$ MILLIONS)	113
TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 (\$ MILLIONS)	114
FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 (\$ MILLIONS)	114
DRUGS IN DEVELOPMENT	114
MAJOR PLAYERS	114
Roche	114
TABLE 33 PATENT EXPIRIES	115
Merck/Bristol-Myers Squibb	115
ISSUES AND TRENDS AFFECTING MARKET	116
SUMMARY	117
CHAPTER 9 GASTRIC CANCER TREATMENT AND PREVENTION MARKET SIZE AND GROWTH	119

TOPIC	PAGE NO.
MARKET BY PRODUCT TYPE	121
CYRAMZA	121
Kadcyla (ado-trastuzumab emtansine)	122
Perjeta	122
Herceptin	123
ONCOLOGY MARKET AND GROWTH	123
Leading Drugs	123
TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 (\$ MILLIONS)	123
MARKET BY GEOGRAPHICAL SEGMENTS	124
TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS)	124
ONCOLOGY PIPELINE	125
U.S. Market	125
JAPAN (ASIA) MARKET	126
TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 (\$ MILLIONS)	126
FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 (\$ MILLIONS)	126
TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 (\$ MILLIONS)	127
FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 (\$ MILLIONS)	127
EUROPE MARKET	128
TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 (\$ MILLIONS)	128
FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 (\$ MILLIONS)	128
TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 (\$ MILLIONS)	128
ASIA MARKET	129
AUSTRALIA MARKET	129
SOUTH KOREA MARKET	129
CHINA MARKET	130
Gastric Cancer Market in China	130
TAIWAN MARKET	131
SINGAPORE MARKET	131
INDIA MARKET	132
BIOMAb-EGFR	133
TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY	133
CHAPTER 10 PIPELINE, PATENTS AND NEW DEVELOPMENTS	135
RECENT DEVELOPMENTS AND APPROVALS	135
TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014	136
NEW DRUGS/COMPANIES IN DEVELOPMENT	136
CLINICAL TRIALS IN ONCOLOGY	136
TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009	136
FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009	136
Two New Clinical Trials for Advanced Gastric Cancer	137
TABLE 43 ROCHE - CLINICAL TRIALS	138
AZD4547	139

TOPIC	PAGE NO.
Pacific Edge	139
Oncolytics	140
CHAPTER 11 GLOBAL CANCER STATISTICS	142
CANCER TRENDS	142
TABLE 44 GLOBAL CANCER ESTIMATES, 2012 (MILLIONS)	142
TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING NON-MELANOMA SKIN CANCER)	143
TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 (MILLIONS)	144
TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012	145
TRENDS OVER TIME	146
FUTURE TRENDS 2020	147
TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%)	147
CANCER CURE AND COSTS	148
CAUSES OF RISE IN CANCER CASES	149
TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION	149
PROJECTIONS TO 2030	150
TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)	150
FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)	151
CURRENT CANCER TRENDS AND ECONOMIC BURDEN	152
The Burden of Cancer	152
EMERGING MARKETS	153
TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 (MILLIONS)	154
TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 (MILLIONS)	154
CANCER PREVALENCE AND MARKET	155
GASTRIC CANCER	156
TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS)	157
TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER	158
AFRICA	158
ASIA	162
Cancer Prevention and Screening in Asia	163
CHINA AND JAPAN	166
Gastric H. pylori infection	169
Japan	169
China	170
MALAYSIA	170
INDIA	170
EUROPE	172
THE AMERICAS	173
TABLE 55 AMERICAS: CANCER FACTS	173
NORTH AMERICA	175
TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014	175
TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014	176
Canada	176
New Cases of Cancer in 2013	177
TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES, BY GENDER, IN CANADA, 2013 (%)	178

TOPIC	PAGE NO.
SUMMARY	178
CHAPTER 12 COMPANIES AND GLOBAL PLAYERS	180
COMPANIES	180
<i>TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 (\$ MILLIONS)</i>	180
CANCER MARKET DYNAMICS	180
SELECTED COMPANIES AND PROFILES	181
BIOGEN IDEC	181
BRISTOL MYERS SQUIBB	181
ELI LILLY AND COMPANY	181
GLAXOSMITHKLINE	182
GENENTECH, INC	183
Hoffmann-LA Roche INC.	183
IMMUNOGEN	183
MERCK & COMPANY	186
NOVARTIS	187
PFIZER	189
ROCHE/GENENTECH	189
ONCOLYTICS	190
PACIFIC EDGE DIAGNOSTICS NZ	191
ZOVA BIOTHERAPEUTICS INC.	191
CHAPTER 13 PARTNERS IN DEVELOPMENT	193
RESEARCH AND DEVELOPMENT PARTNERSHIP AGREEMENTS AND TECHNOLOGY AND DIAGNOSTIC AGREEMENTS	193
CHAPTER 14 REFERENCES	195

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, THROUGH 2020 (\$ MILLIONS)	7
TABLE 1 MAIN CATEGORIES OF CANCER	17
TABLE 2 TYPES OF STOMACH CANCER	29
TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER	29
TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER	30
TABLE 5 RISK FACTORS	32
TABLE 6 CAUSES OF GASTRIC CANCER	33
TABLE 7 SYMPTOMS	33
TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER	40
TABLE 9 GASTRIC SCREENING METHODS	54
TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH CANCER WORLDWIDE, 2012 (THOUSANDS)	60
TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET, THROUGH 2020 (\$ MILLIONS)	62
TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER	64
TABLE 13 TESTS USED TO DETECT H. PYLORI	68
TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 (MILLIONS)	68
TABLE 15 TYPES OF STANDARD TREATMENT	72
TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER	76
TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY THERAPEUTICS	88
TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER TREATMENT	88
TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 (\$ MILLIONS)	89
TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT	91
TABLE 21 CANCER KEY FACTS	96
TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLIONS OF PATIENTS)	98
TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND 2030 (MILLIONS)	99
TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015	100
TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	102
TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013 (\$ MILLIONS/%)	105
TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 (\$ MILLIONS)	106
TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 (\$ MILLIONS)	111
TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT	111
TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2020 (\$ MILLIONS)	112
TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 (\$ MILLIONS)	113
TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 (\$ MILLIONS)	114
TABLE 33 PATENT EXPIRIES	115
TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 (\$ MILLIONS)	123
TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS)	124

TABLE HEADING	PAGE NO.
TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 (\$ MILLIONS)	126
TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 (\$ MILLIONS)	127
TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 (\$ MILLIONS)	128
TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 (\$ MILLIONS)	128
TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY	133
TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014	136
TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009	136
TABLE 43 ROCHE - CLINICAL TRIALS	138
TABLE 44 GLOBAL CANCER ESTIMATES, 2012 (MILLIONS)	142
TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING NON-MELANOMA SKIN CANCER)	143
TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 (MILLIONS)	144
TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012	145
TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%)	147
TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION	149
TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)	150
TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 (MILLIONS)	154
TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 (MILLIONS)	154
TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS)	157
TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER	158
TABLE 55 AMERICAS: CANCER FACTS	173
TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014	175
TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014	176
TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES, BY GENDER, IN CANADA, 2013 (%)	178
TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 (\$ MILLIONS)	180

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, 2014-2020 (\$ MILLIONS)	7
FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 (\$ MILLIONS)	89
FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLION PATIENTS)	98
FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND 2030 (MILLIONS)	99
FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 (\$ MILLIONS)	102
FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 (\$ MILLIONS)	106
FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 (\$ MILLIONS)	111
FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2014-2020 (\$ MILLIONS)	112
FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 (\$ MILLIONS)	113
FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 (\$ MILLIONS)	114
FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER- MONOCLONAL ANTIBODIES, 2014-2020 (\$ MILLIONS)	126
FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 (\$ MILLIONS)	127
FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 (\$ MILLIONS)	128
FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009	136
FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)	151